Corpus Intelligence IC Memo — PEMBROKE HOSPITAL 2026-04-26 07:45 UTC
IC Memo — PEMBROKE HOSPITAL
Investment Committee Memorandum | MA | 120 beds | Grade C | EBITDA uplift $2.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PEMBROKE HOSPITAL

CCN 224023 | NORFOLK, MA | 120 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PEMBROKE HOSPITAL is a 120-bed suburban community hospital in NORFOLK, MA with $33.6M in net patient revenue and a 14.9% operating margin. The hospital serves a payer mix of 14.7% Medicare, 1.0% Medicaid, and 84.3% commercial.

Thesis: Turnaround. Our ML models identify $2.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 14.9% to 22.3% (+736bps).

Net Revenue HCRIS$33.6M
Current EBITDA COMPUTED$5.0M
Operating Margin COMPUTED14.9%
Occupancy HCRIS67.8%
Revenue / Bed COMPUTED$280K
Net-to-Gross HCRIS66.8%
Distress Probability ML48.2%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
58
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 14.9% places it above the state median. Among 58 size-comparable peers (60-240 beds), the median margin is -11.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (60-240), prioritizing same-state peers. 58 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PEMBROKE HOSPITAL (Target)MA120$33.6M14.9%
NEWTON WELLESLEY HOSPITALMA216$624.3M-4.7%
CAPE COD HOSPITALMA239$620.3M-1.3%
BERKSHIRE MEDICAL CENTERMA238$522.9M-12.9%
SAINT VINCENT HOSPITALMA232$404.2M0.2%
CAMBRIDGE HEALTH ALLIANCEMA225$383.9M-50.0%
BETH ISRAEL DEACONESS - PLYMOUMA150$349.1M2.6%
MOUNT AUBURN HOSPITALMA186$337.4M-8.4%
STEWARD ST. ANNES HOSPITALMA175$322.3M12.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$705K+210bp18mo
Cost to Collect4.5%2.5%$671K+200bp12mo
Denial Rate Reduction12.0%6.5%$665K+198bp12mo
A/R Days Reduction5200.0%3800.0%$408K+122bp9mo
Clean Claim Rate88.0%96.0%$21K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$705K
Cost to Collect
$671K
Denial Rate Reduction
$665K
A/R Days Reduction
$408K
Clean Claim Rate
$21K
Total EBITDA Uplift$2.5M
Current EBITDA$5.0M
+ RCM Uplift+$2.5M
Pro Forma EBITDA$7.5M
Current Margin14.9%
Pro Forma Margin22.3%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$7.7M$57.7M7.50x49.6%
Base (11x exit)10.0x11.0x$7.7M$66.0M8.57x53.7%
Bull Case9.0x11.0x$6.9M$76.7M11.06x61.7%
Bull (12x exit)9.0x12.0x$6.9M$85.7M12.36x65.3%
Bear Case11.0x10.0x$8.5M$42.9M5.06x38.3%
Bear (11x exit)11.0x11.0x$8.5M$49.9M5.89x42.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 58 hospitals with 60-240 beds
  • Same-state prioritization (n=59)
  • Comp margins: P25=-18.4% / P50=-11.4% / P75=0.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.